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Effects of Quercetin on Blood Pressure: A Systematic Review and
Meta-Analysis of Randomized Controlled Trials
Maria-Corina Serban, MD, PhD; Amirhossein Sahebkar, PharmD; Alberto Zanchetti, MD, PhD; Dimitri P. Mikhailidis, MD, PhD;
George Howard, DrPH; Diana Antal, PharmD; Florina Andrica, PhD; Ali Ahmed, MD, MPH; Wilbert S. Aronow, MD; Paul Muntner, PhD;
Gregory Y. H. Lip, MD; Ian Graham, MD, PhD; Nathan Wong, MD, PhD; Jacek Rysz, MD, PhD; Maciej Banach, MD, PhD, FNLA, FAHA, FESC,
FASA for the Lipid and Blood Pressure Meta-analysis Collaboration (LBPMC) Group*
Background-—Quercetin, the most abundant dietary flavonol, has antioxidant effects in cardiovascular disease, but the evidence
regarding its effects on blood pressure (BP) has not been conclusive. We assessed the impact of quercetin on BP through a
systematic review and meta-analysis of available randomized controlled trials.
Methods and Results-—We searched PUBMED, Cochrane Library, Scopus, and EMBASE up to January 31, 2015 to identify placebo-
controlled randomized controlled trials investigating the effect of quercetin on BP. Meta-analysis was performed using either a
fixed-effects or random-effect model according to I2 statistic. Effect size was expressed as weighted mean difference (WMD) and
95% CI. Overall, the impact of quercetin on BP was reported in 7 trials comprising 9 treatment arms (587 patients). The results of
the meta-analysis showed significant reductions both in systolic BP (WMD: 3.04 mm Hg, 95% CI: 5.75, 0.33, P=0.028) and
diastolic BP (WMD: 2.63 mm Hg, 95% CI: 3.26, 2.01, P<0.001) following supplementation with quercetin. When the studies
were categorized according to the quercetin dose, there was a significant systolic BP and diastolic BP-reducing effect in
randomized controlled trials with doses ≥500 mg/day (WMD: 4.45 mm Hg, 95% CI: 7.70, 1.21, P=0.007 and 2.98 mm Hg,
95% CI: 3.64, 2.31, P<0.001, respectively), and lack of a significant effect for doses <500 mg/day (WMD: 1.59 mm Hg, 95%
CI: 4.44, 1.25, P=0.273 and 0.24 mm Hg, 95% CI: 2.00, 1.52, P=0.788, respectively), but indirect comparison tests failed to
significant differences between doses.
Conclusions-—The results of the meta-analysis showed a statistically significant effect of quercetin supplementation in the
reduction of BP, possibly limited to, or greater with dosages of >500 mg/day. Further studies are necessary to investigate the
clinical relevance of these results and the possibility of quercetin application as an add-on to antihypertensive therapy. ( J Am
Heart Assoc. 2016;5:e002713 doi: 10.1161/JAHA.115.002713)
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N utraceuticals and flavonoid-containing dietary supple-ments are becoming increasingly popular in the treat-
ment and prevention of cardiovascular disease.1–4 Flavonols,
flavanols, and anthocyanidins are the main members of the
group of natural phenolic compounds called flavonoids.5 The
intervention-based human studies performed as early as
1993 have shown a positive correlation between the dietary
intake of flavonoids and reduced incidence and mortality
from cardiovascular disease.6 The Zutphen Elderly Study has
shown that flavonoids, including quercetin, reduced the risk
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of coronary death by 68% in men who consumed
>29 mg flavonols/day compared with men who consumed
<10 mg flavonols/day.6 Quercetin (3, 30, 40, 5, 7-pentahy-
droxyflavone) has been singled out among flavonoids
because of its ubiquitous presence and abundance in fruits
and vegetables, as such or bound to sugar moieties in
various glycosides.7 Quercetin can be found in apples,
capers, cocoa powder, berries, red grapes, red wine, citrus
fruits, broccoli, onions, bark roots, flowers, green tea, and
black tea.8 This particular flavonol is the subject of about
one third of the 35 000 studies on flavonoids.9 Prominent
effects include antioxidant, anticarcinogenic,10,11 antithrom-
botic,12 anti-allergic,13 antidiabetic,14 antiobesity,15 immune
and inflammation-modulating activities,16 or different cell
signaling effects.17 Anti-atherosclerotic, antiproliferative, and
anti-inflammatory effects of quercetin have been docu-
mented in many human in vitro and in vivo models.18 Its
positive effect on hypertension was documented for the first
time on spontaneously hypertensive rats, in an experimental
model that mimics human hypertension.19 Since then, many
experimental and human studies showed that quercetin
exerts vasodilator, antiplatelet, and antiproliferative effects,
decreasing oxidative status, blood pressure (BP), and end-
organ damage.20–24 The BP-lowering effect of quercetin is
more evident in subjects with certain comorbidities such as
metabolic syndrome or in smokers.25 Different studies tried
to establish a connection between the antihypertensive
effect of quercetin and certain phenotypes such as the
apolipoproteins (apo) E3 and E4, but so far results are
conflicting.26
However, evidence of the effects of quercetin on BP has
not been conclusive. Therefore, we systematically reviewed all
available randomized controlled trials (RCTs) investigating the
impact of quercetin on BP.
Subjects and Methods
Design
This study was designed according to the guidelines of the
2009 preferred reporting items for systematic reviews and
meta-analysis (PRISMA) statement1) SCOPUS (http://
www.scopus.com), Medline (http://www.ncbi.nlm.nih.gov/
pubmed), Cochrane Library (www.cochranelibrary.com), and
EMBASE (http://www.embase.com) databases were
searched using the following search terms in titles and
abstracts (also in combination with MESH terms): (quercetin)
AND (blood pressure). The wild-card term “*” was used to
increase the sensitivity of the search strategy. No language
restriction was used in the literature search. The search was
limited to studies in humans. The literature was searched
from inception to January 31, 2015.
Because of the study design (meta-analysis of RCTs), no
Institutional Review Board approval, as well as no patients’
informed consents were obtained.
Study Selection
Original studies were included if they met the following
inclusion criteria: (1) randomized clinical trial in either parallel
or crossover design versus placebo control, (2) investigated the
impact of quercetin on BP, (3) presentation of sufficient
information on baseline and at the end of study in both
quercetin and control groups, and (4) administering quercetin
for a period of at least 2 weeks. Exclusion criteria were the
following: (1) nonclinical studies, (2) uncontrolled trials, (3) lack
of sufficient information on baseline or follow-up BP, and (4)
administration of an active comparator in the control group.
Data Extraction
Eligible studies were reviewed and the following data were
abstracted: (1) first author’s name; (2) year of publication; (3)
study location; (4) number of participants in the quercetin and
control groups; (5) dose and duration of supplementation with
quercetin; (6) age, sex, and body mass index of study
participants; (7) circulating concentrations of total choles-
terol, low-density lipoprotein cholesterol, high-density lipopro-
tein cholesterol, triglycerides, and glucose; (8) prevalence of
smoking, type 2 diabetes, dyslipidemia, hypertension, and
coronary heart disease; and (9) systolic blood pressure (SBP)
and diastolic blood pressure (DBP).
Access to Study
All authors had access to the study data and reviewed and
approved the final manuscript.
Quality Assessment
A systematic assessment of bias in the included studies was
carried out using the Cochrane criteria.27 The items used for
the assessment of each study were as follows: adequacy of
sequence generation, allocation concealment, blinding,
addressing of dropouts (incomplete outcome data), selective
outcome reporting, and other potential sources of bias.
According to the recommendations of the Cochrane Hand-
book, a judgment of “yes” indicated low risk of bias, while
“no” indicated high risk of bias. Labeling an item as “unclear”
indicated an unclear or unknown risk of bias.
Statistical Analysis
Meta-analysis was conducted using the Comprehensive Meta-
Analysis (CMA) V2 software (Biostat, NJ).28 SBP and DBP were
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collated in mm Hg. SDs of the mean difference were calculated




assuming a correlation coefficient (R)=0.5. In case of reporting
SEM, SD was estimated using the following formula:
SD=SEM9square root (n), where n is the number of subjects.
Net changes in measurements (change scores) were
calculated for parallel and crossover trials, as follows:
(measure at end of follow-up in the treatment groupmeasure
at baseline in the treatment group)(measure at end of
follow-up in the control groupmeasure at baseline in the
control group). Meta-analysis was performed using either a
fixed-effects or random-effect model according to I2 statistic.
I2 values <50% and ≥50% suggested the use of fixed-effects
and random-effects model, respectively. The generic inverse
variance method was used to weight each individual study
included in the meta-analysis. Interstudy heterogeneity was
assessed using Cochrane Q statistic and quantified by I2
statistic. Effect size was expressed as weighted mean
difference (WMD) and 95% CI. In order to evaluate the
influence of each study on the overall effect size, sensitivity
analysis was conducted using the 1-study remove (leave-1-
out) approach.
In the absence of trials making head-to-head comparison,
the effects of different doses and supplementation durations
of quercetin were compared using adjusted indirect compar-
ison according to the method proposed by Song et al29 and
Bucher et al.30 In this method, treatment effects estimated
for each dose or administration duration in the random-effects
model could be compared indirectly through common
controls.
Meta-Regression
Meta-regression was performed in order to evaluate the
association between calculated WMD in SBP and DBP values
with dose and duration of quercetin supplementation in the
included studies. Meta-regression was performed under a
fixed-effects or random-effects (using unrestricted maximum
likelihood method) model according to the results of hetero-
geneity analysis and I2 values. A covariance matrix was built
to assess the covariance between regression coefficients of
different confounders.
Publication Bias
Potential publication bias was explored using visual inspection
of Begg’s funnel plot asymmetry, and Begg’s rank correlation
and Egger’s weighted regression tests. Duval and Tweedie
“trim and fill” and “fail-safe N” methods were used to adjust
the analysis for the effects of publication bias.31
Results
Search Results
The preliminary screening ruled out articles whose titles and/
or abstracts were obviously unimportant. After evaluation, 7
articles with 9 quercetin treatment arms met the inclusion
criteria and were chosen for the final meta-analysis. For
crossover studies with a 292 crossover design, each of the
study arms (placebo-quercetin or quercetin-placebo) was
treated as a separate study. A listing of the study selection
procedure is displayed in Figure 1.
Trial Characteristics
In total, 587 participants were randomized, of whom 299 were
allocated to quercetin supplementation and 288 to the control
group in the 7 selected studies with 9 treatment arms.32–38
The number of participants in these trials ranged from 13 to
93. Included studies were published between 1998 and 2014,
and were conducted in the United States, Iran, Canada,
Germany, and Korea. Ranges of doses from 100 to 1000 mg/
day of quercetin were administered in the included trials.
Duration of supplementation with quercetin ranged between 4
and 10 weeks. Five trials were designed as parallel-group
studies and 2 trials as 292 crossover design. Among all
studies included in this meta-analysis, only 1 study included
men and women with prehypertension and stage 1 hyperten-
sion.35 All other studies included patients without hyperten-
sion. Demographic and baseline parameters of the included
studies are shown in Table 1. Oral quercetin administration
was safe and well tolerated in all of the RCTs included in this
review, with no report of serious adverse events.
Risk of Bias Assessment
The assessment of risk of bias in the included studies using
Cochrane criteria is shown in Table 2.
Effect of Quercetin on SBP
Meta-analysis of data from 9 treatment arms showed
significant reductions in SBP (WMD: 3.04 mm Hg, 95% CI:
5.75, 0.33, P=0.028) following supplementation with
quercetin (Figure 2 upper part). Removal of the study by
Zahedi et al33 from the meta-analysis yielded a nonsignificant
effect size equivalent to 1.78 mm Hg; 95% CI: 4.07, 0.52,
P=0.129. When the RCTs were stratified according to the
duration of supplementation, there was no significant effect
in the subsets of studies lasting <8 weeks (WMD:
2.18 mm Hg, 95% CI: 5.00, 0.64, P=0.130), while a
marginally significant reducing effect was observed in trials
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with ≥8 weeks of follow-up (WMD: 3.57 mm Hg, 95% CI:
7.51, 0.37, P=0.076). Likewise, a significant effect of
quercetin was observed in the subset of trials administering
doses ≥500 mg/day (WMD: 4.45 mm Hg, 95% CI: 7.70,
1.21, P=0.007) but not in the subset with <500 mg/day
doses (WMD: 1.59 mm Hg, 95% CI: 4.44, 1.25, P=0.273)
(Figure 3). When dose classification was set at ≤500 and
>500 mg/day, no significant change was observed in either
of the subgroups (P>0.05 for both). Adjusted indirect
comparison did not suggest any significant difference
between either of the dose (DWMD: 5.01 mm Hg, 95% CI:
9.19, 0.83, Dz-score: 2.35, P>0.05) and supplementa-
tion duration (DWMD: 4.35 mm Hg, 95% CI: 8.46, 0.24,
Dz-score: 2.08, P>0.05) subgroup pairs.
Effect of Quercetin on DBP
Combined analysis of 9 RCT arms revealed a significant
reduction of DBP (WMD: 2.63 mm Hg, 95% CI: 3.26,
2.01, P<0.001) following supplementation with quercetin
(Figure 2 lower part). Removal of the study by Zahedi et al33
yielded an effect size equivalent to 0.98 mm Hg (95% CI:
2.44, 0.49, P=0.191). In subgroup analysis, a marginally
significant effect was found in the subset of trials with
<8 weeks of follow-up (WMD: 1.85 mm Hg, 95% CI: 3.72,
0.02, P=0.053) but not in the subset lasting ≥8 weeks (WMD:
0.88 mm Hg, 95% CI: 3.23, 1.47, P=0.464) (Figure 3).
When the studies were categorized according to administered
quercetin dose, there was a greater DBP-reducing effect in
trials with ≥500 mg/day (WMD: 2.98 mm Hg, 95% CI:
3.64, 2.31, P<0.001) versus those with <500 mg/day
dosage (WMD: 0.24 mm Hg, 95% CI: 2.00, 1.52, P=0.788)
(Figure 4). This result was also consistent when the dose
classification was set at ≤500 and >500 mg/day (P>0.05 and
<0.05, respectively). However, adjusted indirect comparison
did not suggest any significant difference between either of
the dose (DWMD: 2.74 mm Hg, 95% CI: 4.34, 1.14, Dz-
score: 3.36, P>0.05) and supplementation duration (DWMD:
Figure 1. Flow chart of number of studies identified and included in the review.
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0.88 mm Hg, 95% CI: 2.68, 0.92, Dz-score: 0.96,
P>0.05) subgroup pairs.
Meta-Regression Analysis
Potential associations between the antihypertensive effects of
quercetin with dose and duration of supplementation were
evaluated using meta-regression analysis. SBP-lowering effect
of quercetin was associated with duration of supplementation
(slope: 0.92; 95% CI: 1.52, 0.32; P=0.003) but not the
administered dose (slope: 0.003; 95% CI: 0.01, 0.07;
P=0.548). With respect to DBP, there was a dose–response
association (slope: 0.07; 95% CI: 0.01, 0.002; P=0.005)
but the observed effect size was independent of
















Javadi et al 32 L U L L L L L
Zahedi et al 33 L L L L L L L
Conquer et al 34 U U L L L L L
Edwards et al 35 U U L L U L L
Egert et al 36 L U L L L L L
Lee et al 37 U U L L L L L
Pfeuffer et al 38 U U L L L L L
H indicates high risk of bias; L, low risk of bias; U, unclear risk of bias.
Figure 2. Forest plot displaying weighted mean difference and 95% CIs for the impact of quercetin on systolic (upper plot) and diastolic (lower
plot) blood pressures.
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supplementation duration (slope: 0.22; 95% CI: 0.62,
0.18; P=0.276) (Figure 5). Using a covariance matrix analysis
of regression coefficients, the covariance of treatment dose
and duration was 0 for SBP analysis and 0.0001 for DBP
analysis.
Publication Bias
Visual inspection of the funnel plot of SE versus effect size
(mean difference) suggested a potential publication bias for
the impact of quercetin on both SBP and DBP. Using trim-and-
fill correction, 4 and 3 potentially missing studies were
imputed for the analysis of SBP and DBP, respectively. The
imputed effect sizes of quercetin on SBP and DBP were
4.51 mm Hg (95% CI: 6.55, 2.47; P<0.05) and
2.83 mm Hg (95% CI: 3.44, 2.22; P<0.05), respectively
(Figure 6).
In addition to visual inspection of funnel plots, presence of
publication bias was explored using Begg’s rank correlation
test, Egger’s linear regression test, and “fail-safe N” test. The
results of these tests are summarized in Table 3.
Discussion
To our knowledge, the present meta-analysis is the first to
assess the effects of quercetin supplementation on BP based
Figure 3. Forest plot displaying weighted mean difference and 95% CIs for the impact of quercetin on systolic blood pressure in different
subgroups of trials stratified according to the administered quercetin dose and duration of supplementation.
Figure 4. Forest plot displaying weighted mean difference and 95% CIs for the impact of quercetin on diastolic blood pressure in different
subgroups of trials stratified according to the administered quercetin dose and duration of supplementation.
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on the results from RCTs. Meta-analysis of data from 9
treatment arms showed significant reductions in SBP and DBP
following supplementation with quercetin. The estimated
effect sizes for the impact of quercetin on BP were sensitive
only to the study of Zahedi et al.33 The distinctive feature of
this study in comparison to other studies included in the
meta-analysis is recruitment of diabetic subjects. Hence, the
greater effect size observed by Zahedi et al33 might be
attributed to the higher activity of quercetin in diabetic
subjects attributable to the reported hypoglycemic and
insulin-sensitizing activities of this phytochemical in diabetes,
which can eventually lead to attenuation of diabetes-induced
vasoconstriction.7,39 In addition, the heightened state of
oxidative stress in diabetes might justify a more sizable effect
of quercetin as an efficient antioxidant,25 providing another
potential mechanism for the antihypertensive effect of
quercetin.
The calculated BP-lowering effect of quercetin is substan-
tial (3.04, 2.63 mm Hg SBP/DBP), particularly consider-
ing that the cohorts of the studies included were largely made
up of normotensive individuals. When the RCTs were stratified
according to the duration of supplementation, there was no
significant effect in the subsets of studies lasting <8 weeks,
while a marginally significant reducing effect was observed in
trials with ≥8 weeks of follow-up. Likewise, a significant effect
of quercetin was observed in the subset of trials administering
doses ≥500 mg/day, but not in the subset with <500 mg/
day doses. The results indicated a significant antihypertensive
effect of quercetin supplementation on both SBP and DBP. In
interpreting the results of the subanalyses based on length of
administration and dose, caution should be used because of
loss of statistical power attributable to RCT stratification, and
because indirect comparison tests failed to confirm statisti-
cally significant differences. Clearly, studies directly compar-
ing different doses or treatment duration are necessary.
The mechanisms accountable for these effects of quercetin
are not completely understood, with multiple modulation in
cell signaling and gene expression being the most probable.
Some attempts to clarify the mechanism of action of
quercetin in hypertension were performed.40,41 Hypotheses
tested in different experimental and clinical trials included the
following: lowering of oxidative stress,19 interference with the
renin–angiotensin system,42 improvement of endothelial
function,43 downregulation of endothelin-1 expression,44
downregulation of nicotinamide adenine dinucleotide phos-
phate-oxidase,45 increasing of endothelial nitric oxide syn-
thase activity,45 downregulation of angiotensin II 1a receptor
expression in the kidney, or improving the balance between
circulating endothelin-1 and NO.22 Also, the exact contribu-
tion of quercetin metabolites to the overall antihypertensive
effect must be clarified: about 90% of dietary quercetin is not
absorbed and undergoes extensive metabolization by colic
Figure 5. Meta-regression bubble plots of the association between mean changes in systolic and diastolic blood pressure values after
quercetin supplementation with quercetin dose and duration of supplementation. The size of each circle is inversely proportional to the variance
of change.
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microbiota, resulting in phenolic acids, compounds that have
not been investigated yet in the context of hypertension.46
Furthermore, the antihypertensive effects of quercetin and
captopril were similar in an experimental study on Dahl salt-
sensitive rats.22
A challenge to the explanation of quercetin bioactivity was
represented, until recently, by the contradiction between its
extremely low plasma concentration after oral administration
and the demonstrable systemic effects.47 The resolution of
this inconsistency, termed the “flavonoid paradox” came with
the full comprehension of the conjugation–deconjugation
steps of these compounds in humans.9 It has been proven
that after oral absorption, quercetin is rapidly converted to
circulating conjugates through glucuronidation, sulfatation, or
Figure 6. Funnel plot displaying publication bias in the studies reporting the impact of quercetin on
systolic (upper plot) and diastolic (lower plot) blood pressure. The size of each circle is inversely
proportional to the variance of change.
Table 3. Assessment of Publication Bias in the Impact of Quercetin on Blood Pressure
Begg’s Rank Correlation Test Egger’s Linear Regression Test Fail-Safe N Test
Kendall’s Tau* z-Value P Value Intercept 95% CI t df P Value n†
SBP, mm Hg 0.08 0.31 0.754 1.69 0.91, 2.47 5.12 7 0.001 54
DBP, mm Hg 0.08 0.31 0.754 0.94 0.24, 2.13 1.88 7 0.102 31
DBP indicates diastolic blood pressure; SBP, systolic blood pressure.
*With continuity correction.
†Number of theoretically missing studies.
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methylation, as a measure of classical xenobiotic detoxifica-
tion.46 This accounts for the very low aglycone concentra-
tions in human plasma (in the nanomolar range).48 At a
vascular level, quercetin glucuronides, but not sulfoconju-
gates, are freed of their sugar moiety by a deconjugation
process performed by b-glucuronidases, and the free agly-
cone is delivered to tissues.9 Given the importance of
quercetin glucuronide deconjugation, b-glucuronidase activity
is crucial for the therapeutic effectiveness of this flavonol.9
Furthermore, correlations between b-glucuronidase activity
and apo E phenotype49 may explain the efficacy of quercetin
in patients with apo E3 phenotype as opposed to those
expressing apo E4 phenotype.50 On the other hand, an
increased activity of b-glucuronidase under inflammatory
conditions has also been pointed out, raising the hypothesis
that quercetin may be more effective under inflammatory
conditions—a valuable aspect since hypertension may be
associated with comorbidities having an inflammatory com-
ponent.51
Our findings that higher doses (>500 mg) of quercetin
yield greater effect size on BP are to a certain extent opposite
to those obtained in the Cancer Prevention Study II Nutrition
Cohort that reported that even relatively small quantities of
flavonoid-rich foods may be beneficial in reducing the risk of
cardiovascular disease.52 This could be explained by the fact
that the amounts used in most dietary intervention studies are
higher than those used in the general public. Indeed, a recent
trial showed that the habitual intake of flavonoids in Europe is
much below the amounts found to have a significant health
effect.53
Quercetin has a generally recognized as safe status
according to the U.S. Food and Drug Administration; only
some minor side-effects such as headache, nausea, and
tingling of the extremities were observed in long-term
quercetin supplementation at 1000 mg/day.54 In 2011, the
European Food Safety Authority released a variety of health
claims underlying the protective effects of quercetin against
oxidative damage.55 Considering the seasonality of food
extracts of flavonoids, the Recommended Dietary Allowance
of total flavonoids might be between 250 and 400 mg/day.56
This meta-analysis has several limitations. Most impor-
tantly, eligible RCTs involved in this meta-analysis had small
populations and short durations of follow-up. The number of
included studies also was not large enough to allow robust
subgroup analyses. Moreover, there is considerable hetero-
geneity in the groups studied: females with rheumatoid
arthritis, females with diabetes, healthy people, overweight
high-risk subjects, and male smokers. Finally, most of the
individuals included were normotensive or prehypertensive. It
will be necessary to evaluate the effects of quercetin
supplementation on long-term control of hypertension and
its complications.
In conclusion, the results of this meta-analysis showed a
significant effect of quercetin supplementation in the reduc-
tion of BP, which suggest that this nutraceutical might be
considered as an add-on to antihypertensive therapy. Further
well-designed trials are necessary to elucidate the clinical
value of quercetin supplementation in hypertension therapy,
to adjust the dosage, and to explore possible drug interac-
tions between quercetin and antihypertensive drugs, as this
flavonol is metabolized by the cytochrome P450 system.57,58
Additional long-term studies on quercetin safety at pharma-
cological doses are warranted as well, since quercetin
supplementation as an antihypertensive implies a 10- to 60-
fold increase in its average dietary intake. Exploration of
possibly greater benefits of quercetin supplementation in
RCTs among hypertensive and/or diabetic populations merits
further investigations.
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